1 studies demonstrated
improved patency relative to PTA without drug coating but
were limited by small sample sizes, heterogeneous patient
populations, and incomplete follow-up. Two larger regulatory trials (LEVANT 2, IN.PACT SFA216) have recently reported improved patency for drug-coated versus uncoated
balloon angioplasty in femoropopliteal disease. As a result,
the FDA has recently approved two drug-coated balloon devices for the